
Personalis Inc (PSNL) Stock Forecast & Price Target
Personalis Inc (PSNL) Analyst Ratings
Bulls say
Personalis Inc has demonstrated significant potential for growth, as indicated by a 28% increase in stock value following the announcement of Medicare coverage for its NeXT Personal MRD test, which showcases its effectiveness in early cancer recurrence detection. The company's strategic decision to temporarily ease volume growth in Q3 to manage cash burn has positioned it to capitalize on future demand, particularly with anticipated marketing acceleration by its commercial partner Tempus. Furthermore, positive reimbursement outcomes for its breast cancer indication have prompted a reassessment of revenue projections for additional indications, signaling a favorable trajectory for sales estimates into 2026 and beyond.
Bears say
Personalis Inc. faces a negative outlook primarily due to revised revenue expectations, with the company lowering its 2025 revenue guidance from $70-$80 million to $68-$73 million, indicating a year-over-year decline of 5% to 12%. The reduction is attributed to uncertainties in sample flow for minimal residual disease (MRD) testing and delays in reimbursement approvals for clinical sample testing, which are impacting biopharma revenues significantly. Additionally, the company's continued losses and the presence of debt on its balance sheet raise concerns about its ability to achieve and maintain profitability in the future.
This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.
Personalis Inc (PSNL) Analyst Forecast & Price Prediction
Start investing in Personalis Inc (PSNL)
Order type
Buy in
Order amount
Est. shares
0 shares